Introduction
============

There is growing evidence that cardiovascular disease (CVD) is a risk factor for cognitive dysfunction long prior to onset of stroke or dementia ([@b32-ndt-2-213]; [@b23-ndt-2-213]; [@b18-ndt-2-213]; [@b13-ndt-2-213]; [@b37-ndt-2-213]; [@b47-ndt-2-213]). These findings are consistent with the notion of vascular cognitive impairment (VCI), a proposed continuum of cognitive deficits that ranges from "brain at risk" to vascular dementia ([@b21-ndt-2-213]; [@b5-ndt-2-213]). Older adults with CVD are believed to fall in the middle of this continuum, exhibiting cognitive deficits and cerebrovascular disease without the functional impairment found in dementia ([@b32-ndt-2-213]; [@b23-ndt-2-213]; [@b18-ndt-2-213]; [@b13-ndt-2-213]; [@b37-ndt-2-213]; [@b47-ndt-2-213]; [@b8-ndt-2-213]; [@b27-ndt-2-213]).

Given these findings, it is not surprising that older adults with CVD often report experiencing significant cognitive dysfunction in everyday life ([@b25-ndt-2-213]). However, less straightforward is the fact that these reports are more closely related to depressive symptoms than objective test performance ([@b36-ndt-2-213]; [@b25-ndt-2-213]; [@b4-ndt-2-213]). Such findings suggest that older CVD patients lack insight into their level of cognitive function. Reduced awareness of cognitive function is not unique to CVD patients and is found in persons with a variety of psychiatric and neurological conditions. For example, persons with bipolar disorder and patients in the early stages of dementia also exhibit little awareness of their impairments ([@b6-ndt-2-213]; [@b44-ndt-2-213]).

However, methodological concerns of past studies encourage a re-examination of the relationship between subjective and objective cognitive impairment in CVD patients. Careful review shows that previous work often examined only cardiothoracic surgery patients, selected predictors from limited domains (ie, only cognitive and affective), and employed tests that tap cognitive abilities other than those patients report as being impaired ([@b36-ndt-2-213]; [@b25-ndt-2-213]; [@b38-ndt-2-213]). Each of these methodological choices may distort the observed relationship between reported cognitive dysfunction and test performance, raising the possibility that reports of cognitive dysfunction in CVD patients may not be as inaccurate as originally believed.

To clarify this possibility, the present study examined self-reported cognitive dysfunction in older adults with heterogeneous history of CVD. Variables were chosen to closely match those used in past studies and to extend the assessment of cognitive abilities that patients reported as being impaired. Using this method, we hypothesized that multiple factors, including cognitive performance, would be related to self-reported cognitive dysfunction of older adults with CVD.

Methods
=======

The following methods were approved by the local Institutional Review Board prior to study onset.

Participants
------------

Participants included 84 older adults enrolled in a prospective study of the neurocognitive consequences of CVD. They were required to have a documented history of CVD, a total score on the Mini Mental Status Examination (MMSE) above cutoff for dementia ([@b14-ndt-2-213]), and no history of neurological or severe psychiatric disorder. Participants were recruited from cardiology clinic patients and not selected based on concerns regarding possible cognitive dysfunction. Participants averaged 69.79 ± 7.87 years of age and 14.41 ± 2.72 years of education. Average MMSE score (28.52 ± 1.67) and cardiac ejection fraction (58.87 ± 11.65) were within normal ranges.

In terms of medical history, 46% of participants had a history of myocardial infarction, 37% coronary artery bypass, 11% valve repair or replacement, 13% heart failure, 74% hypertension, and 23% type 2 diabetes. Approximately 10% of participants had prior history of mild head injury, 9% transient ischemic attack, and 13% had history of depression.

Instrumentation
---------------

### Subjective cognitive complaints

The Cognitive Difficulties Scale (CDS) is a pen-and-paper measure of subjective difficulties in attention, memory, perception, and psychomotor abilities ([@b33-ndt-2-213]). It has been used in both healthy and patient samples, including persons with CVD ([@b33-ndt-2-213]; [@b10-ndt-2-213]; [@b11-ndt-2-213]; [@b25-ndt-2-213]). The relationship among the CDS, depression, and cognitive function varies across studies. Although some studies show a strong relationship between the CDS and performance on neuropsychological tests, others find the CDS is more closely related to affective symptoms than cognitive dysfunction ([@b19-ndt-2-213]; [@b11-ndt-2-213]; [@b25-ndt-2-213]; [@b6-ndt-2-213]; [@b44-ndt-2-213]).

### Neuropsychological tests

All participants completed a neuropsychological test battery comprising tasks commonly used during clinical neuropsychological evaluation ([Table 1](#t1-ndt-2-213){ref-type="table"}). Domains included:

1.  *Attention* (Trailmaking Test Part A \[[@b39-ndt-2-213]\], Digit Symbol-Coding \[[@b49-ndt-2-213]\], Digit Span \[[@b49-ndt-2-213]\], Stroop Color Word Test composite score for Word and Color trials \[[@b17-ndt-2-213]\]);

2.  *Executive function* (Trail Making Test B \[[@b39-ndt-2-213]\], Lexical Fluency \[FAS; Eslinger et al 1984\], Similarities \[[@b49-ndt-2-213]\], Stroop Color Word Test Interference \[[@b17-ndt-2-213]\]);

3.  *Memory* (California Verbal Learning Test \[[@b9-ndt-2-213]\], Brief Visuospatial Memory Test-Revised \[[@b3-ndt-2-213]\]);

4.  *Language* (Boston Naming Test ([@b24-ndt-2-213]\], Category Fluency \[[@b35-ndt-2-213]\]);

5.  *Visuopatial skills* (Hooper Visual Organization Test \[[@b22-ndt-2-213]\], Block Design \[[@b49-ndt-2-213]\]);

6.  *Motor function* (Grooved Pegboard Test for dominant and nondominant hand \[[@b26-ndt-2-213]\]).

### Depression

The Beck Depression Inventory (BDI) assesses vegetative, affective, and cognitive symptoms of depression and has been used extensively in patient populations ([@b2-ndt-2-213]; [@b40-ndt-2-213]).

### Quality of life

The Medical Outcomes Study SF-36 ([@b48-ndt-2-213]) is a measure of subjective health used extensively in healthy and medical populations, including persons with CVD ([@b42-ndt-2-213], [@b41-ndt-2-213]). Its eight domains were summarized into a Physical Composite Summary (PCS) and Mental Composite Summary scores (MCS), representing physical and mental quality of life, respectively.

#### Procedure

After participants completed a written informed consent process, all instruments were administered in a one-to-one format by trained research team members. Participants completed self-report instruments after neuropsychological testing.

#### Data analysis

Three sets of analyses were conducted to better understand the self reported cognitive dysfunction of older adults with CVD. First, bivariate Pearson correlation was used to determine the relationship between reported difficulties on the CDS and objective test performance. An item analysis was then conducted to identify the cognitive abilities of greatest concern in our sample. Finally, exploratory regression analyses were conducted to determine the relative contribution of various factors to CDS total score. More specifically, we conducted multiple regression with backward elimination using CDS total score as the dependent variable. Predictors included demographic characteristics, measures of cardiovascular disease, depressive symptoms, quality of life, and performance on tests that tap the most commonly reported areas of dysfunction.

Results
=======

Test performance and reported cognitive dysfunction
---------------------------------------------------

Participants typically performed well on neuropsychological testing, with their combined performance falling within 1.5 standard deviations of the normative mean on all tests ([Table 1](#t1-ndt-2-213){ref-type="table"}). Bivariate correlation showed that CDS total score was significantly related to depressive symptoms on the BDI, quality of life indices from the SF-36, and performance on multiple neuropsychological tests ([Table 1](#t1-ndt-2-213){ref-type="table"}).

Item analysis
-------------

An item analysis was then conducted on the CDS. Corrected item-total correlations were used to identify the cognitive tasks of greatest concern to our sample of older adults with CVD. Results showed that difficulties with distractibility and sustained attention were most common, followed by language difficulties ([Table 2](#t2-ndt-2-213){ref-type="table"}).

Predicting reported cognitive dysfunction
-----------------------------------------

Finally, exploratory regression analyses were conducted to examine the relative contribution of various factors to the subjective cognitive difficulties of older adults with CVD. Stepwise regression with backward elimination showed significant prediction of CDS total score (F\[3, 56\] = 13.31, p \< 0.001), with the final model accounting for 41.6% of the variance ([Table 3](#t3-ndt-2-213){ref-type="table"}). Three predictors remained significant, namely: BDI total score, PCS from the SF-36, and speeded sustained attention from the Stroop Color Word Test. Demographic variables, cardiac output, and other cognitive tests were not retained in the final model.

Discussion
==========

The present study is the first to demonstrate that attention and language abilities are the most common cognitive concerns of older CVD patients. Reduced attentional abilities may be expected in persons with CVD, as they often show reduced performances on neuropsychological tasks tapping attention, psychomotor speed, and executive function ([@b32-ndt-2-213]; [@b23-ndt-2-213]; [@b18-ndt-2-213]; [@b13-ndt-2-213]; [@b37-ndt-2-213]; [@b47-ndt-2-213]). Language impairment is not traditionally associated with CVD in the absence of stroke, though word-finding difficulties are part of both the normal aging process and a symptom of Alzheimer's disease ([@b31-ndt-2-213]; [@b46-ndt-2-213]). Finding that language performance was within expected ranges implicates normal aging as a likely cause, but the very early effects of a neurodegenerative process cannot be fully ruled out. Prospective examination of our and other samples of CVD patients will help clarify whether reported word-finding difficulties predict later conversion to Alzheimer's disease.

In the present study, reports of cognitive dysfunction were associated with reduced performance on multiple cognitive tests. However, the observed relationships were modest in size (range from −0.19 to −0.36) and explained little of the total variance. In contrast, depressive symptoms were closely related to reports of cognitive dysfunction (r = 0.55). Finding reported cognitive problems are more closely related to depressive symptoms than actual test performance is consistent with many past studies ([@b36-ndt-2-213]; [@b25-ndt-2-213]; [@b38-ndt-2-213]), though the exact reason for this relationship remains unclear. Several possible explanations for this finding exist, including shared method variance, the known effects of subclinical depression on cognitive performance, or an as yet unidentified factor ([@b50-ndt-2-213]).

Analyses also showed that quality of life contributes to the report of cognitive dysfunction in older adults with CVD. A relationship between quality of life and reported cognitive dysfunction has previously been found in healthy and other patient populations ([@b7-ndt-2-213]; [@b12-ndt-2-213]; [@b29-ndt-2-213]). Physical illness is known to limit cognitive performance in several ways, including greater distraction, hypervigilance, and preoccupation during tasks ([@b30-ndt-2-213]; [@b15-ndt-2-213]). These changes would adversely impact the same attentional abilities reported by our sample as being impaired. However, once again, the effects of shared method variance on this relationship cannot be fully excluded and replication in other samples is needed.

The present findings highlight the complicated relationship among reported cognitive dysfunction, depression, and actual test performance. Like many others, we found a weak relationship between reported cognitive dysfunction and actual test performance. This pattern emerged in our sample with intact test performance. Interestingly, reported cognitive dysfunction is also unrelated to actual test performance in Alzheimer's patients and psychiatric samples with significant cognitive impairment ([@b6-ndt-2-213]; [@b44-ndt-2-213]). This pattern suggests two likely explanations. One possibility is that people generally have little insight into their level of cognitive function. This inability may well result from the difficulty in accurately evaluating cognitive function in everyday life or the effects of limited executive functioning (which has been associated with reduced awareness in patient populations ([@b34-ndt-2-213]; [@b43-ndt-2-213]; [@b28-ndt-2-213]). A second possible explanation involves the use of cross sectional methodology. It is possible that between-subject differences (eg, level of depressive symptoms) obscure more subtle within-subject changes (eg, reporting a slight change from previous levels). Prospective examination of reported cognitive dysfunction and actual test performance are much needed, particularly studies that collect detailed information regarding subjective change in cognitive function.

The present study has important implications for clinicians working with older adults with CVD. Based on the present findings, CVD patients reporting cognitive dysfunction are most appropriately referred for neuropsychological evaluation to determine the relative contribution of depressive symptoms, reduced quality of life, and actual cognitive impairment to these complaints. Clinicians may also want to consider additional referral to exercise or rehabilitation program, as they are associated with improved mood, quality of life, and cognitive performance in both healthy and patient populations ([@b1-ndt-2-213]; [@b45-ndt-2-213]; [@b20-ndt-2-213]).

This study was supported in part by F32-HL74568 (JG), R01-AG017975 (RAC), and K23-MH065857 (RPH).

###### 

Neuropsychological test performance, impairment and correlation to reported cognitive dysfunction

  Test                                Mean (SD)        \> 1.5 SD from mean   Correlation to CDS
  ----------------------------------- ---------------- --------------------- ------------------------------------------------
  *Reported cognitive difficulties*                                          
  CDS total score                     37.32 (21.56)    No                    --
  *Attention*                                                                
  Trials A                            37.76 (12.44)    No                    0.25[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  Stroop Word and Color               43.52 (5.83)     No                    −0.36[2](#tfn2-ndt-2-213){ref-type="table-fn"}
  WAIS-III Digit Span                 17.51 (3.95)     No                    −0.14
  WAIS-III Symbol Coding              55.40 (13.89)    No                    −0.19[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  *Executive function*                                                       
  Stroop Interference                 −13.65 (6.87)    No                    0.15
  Trials B                            99.57 (51.47)    No                    0.17
  Lexical Fluency (FAS)               36.33 (11.84)    No                    −0.17
  WAIS-III Similarities               20.96 (5.24)     No                    −0.14
  *Memory*                                                                   
  CVLT Trials 1--5 Total              46.58 (11.90)    No                    −0.21[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  CVLT Short Free Recall              9.23 (3.29)      No                    −0.10
  CVLT Long Free Recall               9.30 (3.52)      No                    −0.14
  CVLT Discrimination                 91.33 (7.59)     No                    −0.15
  BVMT Trials 1--3 Total              16.83 (6.98)     No                    −0.23[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  BVMT Delayed Recall                 6.94 (3.18)      No                    −0.22[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  BVMT Discrimination                 5.05 (1.15)      No                    −0.24[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  *Language*                                                                 
  Boston Naming Test                  54.52 (5.65)     No                    −0.19[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  Category Fluency (Animals)          19.90 (5.53)     No                    −0.05
  *Visuospatial*                                                             
  HVOT                                23.44 (3.74)     No                    0.03
  WAIS-III Block Design               31.85 (11.18)    No                    −0.10
  *Motor*                                                                    
  Grooved Pegboard (D)                95.91 (26.37)    No                    0.10
  Grooved Pegboard (ND)               106.61 (33.41)   No                    0.10
  *Mood*                                                                     
  Beck Depression Inventory           5.93 (4.49)      No                    0.55[2](#tfn2-ndt-2-213){ref-type="table-fn"}
  *Quality of life*                                                          
  Physical Component Scale            42.73 (9.50)     No                    −0.28[1](#tfn1-ndt-2-213){ref-type="table-fn"}
  Mental Component Scale              55.01 (7.73)     No                    −0.45[2](#tfn2-ndt-2-213){ref-type="table-fn"}

Note: All test scores are raw scores.

two-tailed p \< 0.05.

two-tailed p \< 0.01.

**Abbreviations:** BVMT, Brief Visuospatial Memory Test-Revised; CVLT, California Verbal Learning Test; CDS, Cognitive Difficulties Scale; D, dominant hand; ND, nondominant hand; HVOT, Hooper Visual Organization Test; WAIS, Wechsler Adult Intelligence Scale.

###### 

Most common subjective cognitive problems in older adults with cardiovascular disease

  Rank correlation                                                            Corrected item-total Item
  --------------------------------------------------------------------------- ---------------------------
  1 I cannot keep my mind on one thing.                                       0.76
  2 I miss the point of what others are saying.                               0.75
  3 I have trouble getting out information that is at the tip of my tongue.   0.71
  4 I find it hard to keep my mind on a task or job.                          0.70
  5 I find it hard to understand what I read.                                 0.68
  6 I forget right away what people say to me.                                0.68
  7 I need to have instructions repeated several times.                       0.68
  8 I have trouble describing a program that I just watched on television.    0.66
  9 When interrupted during reading, I have trouble finding my place again.   0.66
  10 I have to do things very slowly to make sure I'm doing them right.       0.65

###### 

Predicting cardiovascular disease (CVD) total score in older adults with CVD

  Included variables           B       b                      p
  ---------------------------- ------- ---------------------- -------------------------
  Beck Depression Inventory    2.18    0.45                   \< 0.01
  Physical Quality of Life     −0.48   −0.21                  0.05
  Stroop Sustained Attention   −1.10   −0.30                  \< 0.01
  Intercept                    92.80                          
                                       R^2^ = 0.42            
                                       Adjusted R^2^ = 0.39   
                                       R = 0.66               
  **Excluded variables**       **B**   **p**                  **Partial correlation**
                                                              
  Age                          0.03    0.78                   0.04
  Education                    −0.12   0.26                   −0.15
  Cardiac Output               0.12    0.27                   0.15
  Mental Quality of Life       −0.19   0.16                   −0.19
  Digit Symbol-Coding          −0.04   0.77                   −0.04
  CVLT Trial 1                 −0.05   0.63                   −0.07
  FAS                          0.04    0.73                   0.05
  Boston Naming Test           −0.13   0.22                   −0.17

**Abbreviations:** CVLT, California Verbal Learning Test.
